• Liproxstatin-1 HCl: Ferroptosis Assay Workflows

  2026-09-13

  Build a controlled ferroptosis assay around Liproxstatin-1 HCl, using lipid-peroxidation rescue, pathway-selective controls, and formulation safeguards. The workflow also connects cellular experiments with mitochondrial calcium–GPX4 biology and preclinical acute renal failure or hepatic ischemia/reperfusion injury models.

• Syringin: Mechanism and RCC Research Workflow

  2026-09-12

  Syringin is a phenylpropanoid glycoside used in natural product research and bioactive compound screening. A 2024 cell-based study associated Syringin with reduced renal cell carcinoma phenotypes, increased apoptosis, and enhanced sunitinib sensitivity through EGFR/PI3K/Akt signaling.

• EPZ5676: Practical DOT1L Inhibitor Workflows

  2026-09-11

  EPZ5676 combines subnanomolar DOT1L potency with strong methyltransferase selectivity, making it useful for connecting biochemical inhibition to H3K79 methylation and leukemia-cell phenotypes. This guide translates that profile into reproducible enzyme, chromatin, and MLL-rearranged leukemia workflows, with practical controls and troubleshooting advice.

• Hydroxychloroquine Sulfate Workflow Guide

  2026-09-11

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous-compatible research reagent for investigating autophagy pathway modulation and TLR7/9-dependent immune signaling in autoimmune disease research. It is suited to short-term cell and animal-model workflows, but not to protocols requiring DMSO or ethanol solubility or prolonged storage of prepared solutions.

• SB 202190 for CRC Organoid Treg Assays

  2026-09-10

  Use SB 202190 as a timed p38 MAP kinase inhibitor to test whether colorectal cancer organoids drive regulatory T-cell differentiation through p38-dependent signaling. The workflow combines transwell co-culture, pathway-level controls, transcriptomics, and functional suppression assays for more informative cancer therapeutics research.

• FK866 (APO866): Reliable NAMPT Assays

  2026-09-10

  This scenario-driven guide explains how FK866 (APO866), SKU A4381, can improve the interpretation of cell viability, proliferation, and cytotoxicity assays through controlled NAMPT inhibition. It connects potency, solvent handling, assay design, and NAD biology while distinguishing established evidence from practical workflow recommendations.

• Perospirone: Receptor and Kv1.5 Evidence

  2026-09-09

  Perospirone, also called SM-9018 free base, combines high-affinity 5-HT2A and D2 receptor antagonism with 5-HT1A partial agonism. Recent cellular evidence identifies concentration-dependent inhibition of vascular Kv currents and supports a defined cardiovascular safety-screening use in addition to schizophrenia research.

• N-MYC–eIF4G1 Signaling in inv(16) AML

  2026-09-09

  The reference study identifies N-MYC as a previously underappreciated survival regulator in inv(16) acute myeloid leukemia and establishes eIF4G1 as a key downstream effector. By integrating transcriptomic, regulatory, genetic, primary-cell, and xenograft evidence, the work connects CBFβ-SMMHC-associated leukemogenesis with a targetable N-MYC/eIF4G1 dependency.

• Apicidin: An HDAC Probe for Context-Rich Assays

  2026-09-08

  Apicidin is a histone deacetylase inhibitor whose effects extend from cancer-cell phenotypes to meiotic and reproductive toxicology. This article explains how to interpret HDAC engagement, acetylation changes, and cell-state outcomes without confusing a useful research probe with a single-pathway explanation.

• Levofloxacin Workflows for Resistance and Cell Assays

  2026-09-08

  Levofloxacin can connect bacterial DNA replication studies with quantitative osteoblast and cartilage-metabolism assays. This practical guide converts resistance-surveillance findings into controlled workflows, assay checkpoints, and troubleshooting decisions without treating research observations as clinical dosing guidance.

• VX-745: Practical p38α MAPK Inhibition Workflows

  2026-09-07

  VX-745 combines strong p38α preference with practical workflows for cytokine profiling, multiple myeloma research, aging-related fibroblast studies, and inflammatory disease modeling. This guide connects concentration planning, phospho-signaling assays, cytokine endpoints, and troubleshooting without treating kinase inhibition as a one-readout experiment.

• Stable-Isotope UHPLC–MS/MS for 1-Methyl Ado

  2026-09-07

  The 2024 Analytical Chemistry study presents a stable isotope-diluted UHPLC–ESI–MS/MS method for simultaneously quantifying 12 purine ribonucleosides, including 10 methylated species. Ammonium bicarbonate-enhanced ionization, solid-phase extraction, and chromatographic isomer separation improved sensitivity and enabled intracellular measurement of modified nucleosides relevant to RNA modification research and biomarker discovery.

• Hexose Diphosphate: Metabolic Assay Workflows

  2026-09-05

  Build water-based hexose diphosphate workflows for glycolytic regulation, ischemia models, and carefully controlled inflammation assays. The guide also separates this hexose phosphate from phosphoenolpyruvate, helping researchers translate aging-inflammation findings without misassigning mechanism.

• Luminescent ATP Cell Viability Assay Kit I for GBM

  2026-09-04

  The Luminescent ATP Cell Viability Assay Kit I enables rapid, sensitive cell viability measurement across low-to-high cell densities, making it useful for glioblastoma proliferation, drug-response, and cytotoxicity workflows. Its luciferase luminescence detection provides a practical endpoint for translating cytostatic findings into quantitative assay data while preserving the need for orthogonal mechanistic tests.

• GLI2–PRDX1 Ferroptosis Resistance in Bladder Cancer

  2026-09-04

  A 2026 Apoptosis study identifies a GLI2–PRDX1 transcriptional axis that suppresses ferroptosis and promotes bladder cancer progression. Its combination of public-data analysis, RNA sequencing, ChIP, loss-of-function, and rescue experiments supports GLI2 inhibition as a strategy for increasing sensitivity to PRDX1-targeting compounds and cisplatin.

8046 records 5/537 page Previous Next 12345 下5页 Last page